| 生物活性 | Ramatroban is a selective thromboxane A2 (TxA2, IC50=14 nM) antagonist that also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding. |
| IC50 & Target | DP2 (human):33.4 μM, TXA2:14 nM, CRTH2:113 nM |
| 体外研究 (In Vitro) |
Ramatroban is a potent human thromboxane receptor (hTP) antagonist with an IC50 of 18 nM in a human TP binding assay. Ramatroban inhibits prostaglandin D2 receptor DP2 (CRTH2) with an IC50 of 113 nM in a human DP2 binding assay. Ramatroban also inhibits human CYP isoform CYP2C9 with an IC50 of 15 μM. Ramatroban is a selective thromboxane-type prostanoid (TP) receptor antagonist. PGD2-stimulated human eosinophil migration is shown to be mediated exclusively through activation of CRTH2, and surprisingly, these effects are completely inhibited by Ramatroban. Ramatroban is an antagonist for CRTH2, and inhibits PGD2-induced migration of eosinophils via CRTH2 blockade. 3H-labeled PGD2 binds to a single site on CRTH2 transfectants with high affinity (KD=6.3 nM, Bmax=450 pM). Nonlabeled PGD2 inhibits the binding of 3H-labeled PGD2 to CRTH2 transfectants in a concentration-dependent manner with an EC50 value of 2.7 nM. Ramatroban shows significant inhibitory effects on the binding of 3H-labeled PGD2 to CRTH2, albeit with much lower potency (IC50=100 nM). Ramatroban also inhibits PGD2-induced Ca2+ mobilization in CRTH2 transfectants to almost the same extent with an IC50 value of 30 nM. Ramatroban completely inhibits the PGD2-induced migration of eosinophils in a concentration-dependent manner with an IC50 value of 170 nM. |
| 体内研究 (In Vivo) |
Ramatroban is an orally bioavailable small molecule antagonist of CRTH2. Systemic administration of Ramatroban (30 mg/kg) in CRTH2+/+ mice produces the same effects as seen in CRTH2 deficiency. Ramatroban completely blocks LPS-induced decreases in social and object exploratory behavior (p<0.01). In addition, tumor-impaired social interaction and object exploratory behavior in CRTH2+/+ mice are completely reversed by a single injection of Ramatroban, even when the tumor is enlarged. |
| 性状 | 固体 |
| 颜色 | White to off-white |
| 分子量 | 416.47 |
| 分子式 | C21H21FN2O4S |
| CAS No. | 116649-85-5 |
| 别名 | 雷马曲班; BAY u3405 |
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.14 mg/mL (17.14 mM), Solution. 10% DMSO+90% Saline: < 7.14 mg/mL (17.14 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 储存方式 |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
溶液配制表
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DMSO 中的溶解度 : 125 mg/mL (300.14 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。